Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:

Eclipse's PACIFIC Trial Suggests Improved Outcomes For PTMR Patients

This article was originally published in The Gray Sheet

  • News

Executive Summary

Eclipse Surgical's PACIFIC trial evaluating percutaneous transmyocardial revascularization (PTMR) for refractory angina shows a significant increase in patients' exercise tolerance, but leaves open the question of whether or not they experience a placebo effect from the procedure.

You may also be interested in...



Eclipse Axcis PTMR Clinical Data Could Bring Approval In September

Eclipse Surgical expects the PMA for its Axcis percutaneous transmyocardial revascularization (PTMR) device to receive less resistance from FDA's Circulatory System Devices Advisory Panel than was encountered in the review of the company's TMR product in 1998.

Eclipse Axcis PTMR Clinical Data Could Bring Approval In September

Eclipse Surgical expects the PMA for its Axcis percutaneous transmyocardial revascularization (PTMR) device to receive less resistance from FDA's Circulatory System Devices Advisory Panel than was encountered in the review of the company's TMR product in 1998.

Laser Myocardial Therapies Under The Beam In Light Of J&J DIRECT Results

Results of a Johnson & Johnson-sponsored trial showing that direct myocardial revascularization (DMR) technology has a placebo-comparable effect should prompt FDA to take a closer look at laser therapies for advanced heart disease patients, trial investigators suggest.
Table

View full table

Related Content

Medtech Insight
Tags:
UsernamePublicRestriction

Register

MT014168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By